Landmark Nature Paper Unveils Groundbreaking Covalent Inhibitor for Rare Disease
Vividion Therapeutics, a biopharmaceutical company, has made a significant discovery in the development of novel cancer and immune disorder...
Exgenesis Bio: Positive Phase 1/2 Clinical Trial Data for EXG001-307 Gene Therapy for Spinal Muscular Atrophy
Exegenesis Bio, a leading genetic medicines company, unveiled encouraging clinical efficacy and safety results for their EXG001-307 gene therapy...
Incyte’s Acquisition: Unlocking a Promising Pipeline of Groundbreaking Medicines
Incyte, a renowned biopharmaceutical company, has acquired Escient Pharmaceuticals, a pioneer in developing small molecule therapeutics for immune disorders....
Exciting New Clinical Trial Results for Duchenne Muscular Dystrophy
The international gene therapy trial for Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD) using GNT0004 has unveiled promising findings at...
Medpace First Quarter 2024: Strong Financial Gains
Medpace Holdings reported a significant financial performance for the first quarter of 2024. Revenue soared by 17.7% to $511...
Anktiva®: An FDA-Approved Game-Changer for Non-Muscle Invasive Bladder Cancer
The U.S. Food and Drug Administration (FDA) has granted approval for ANKTIVA, a novel immunotherapy, in combination with Bacillus...
Azitra Unveils Breakthrough Gene Therapy Findings in Netherton Syndrome
Azitra, a biopharmaceutical company specializing in dermatology therapies, announced promising preclinical data demonstrating the potential of its platform for...
Neurogene’s Revolutionary Gene Therapy for Rett Syndrome: Exciting Data Unlocks Hope
Neurogene’s NGN-401 gene therapy for Rett syndrome has exhibited promising safety results in initial clinical trials. After several months...
Lantern Pharma’s Harmonic™ Trial Expands to Japan and Taiwan
Lantern Pharma has received regulatory approval to expand its Phase 2 clinical trial (HarmonicTM) to evaluate the efficacy of...
EMBLAVEO Granted Marketing Authorization in the EU for Life-Saving Antibacterial for Resistant Infections
The European Commission has approved EMBLAVEO® (aztreonam-avibactam) as a treatment for severe infections caused by Gram-negative bacteria. This includes...